Research
Our response to “gremlin therapy” research that suggests pancreatic cancer can be reversed
Our Head of Research at Pancreatic Cancer UK, Dr Chris MacDonald has provided commentary on new research from the Institute of Cancer Research which suggests that it could be possible to reverse a key process that enables pancreatic cancer cells to grow and spread in the body.
Our Research Involvement Network: Shaping the future of pancreatic cancer research
Dr Naureen Starling is a Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust specialising in the treatment of gastrointestinal cancers, as well as researching new therapies.
Presentations from Discovery and Translational Research Forum
Our response to the mRNA pancreatic cancer vaccine trial
Our Head of Research, Dr Chris MacDonald comments on the exciting trial results presented at the American Society of Clinical Oncology conference in Chicago.
Pancreatic Cancer UK Discovery and Translational Research Forum, 13 & 14 June 2022
New research project: what is pancreatic exocrine insufficiency and how can we diagnose it more quickly?
Pancreatic exocrine insufficiency (PEI) occurs when the pancreas becomes unable to produce enough enzymes to break down food, and effectively causes the body to starve. The condition affects 60-90% of people with pancreatic cancer.
Pancreatic Cancer UK’s Research in Scotland: Changing the future of pancreatic cancer, 28th March 2022
What’s the link between diabetes and pancreatic cancer?
Over 40% of people living with pancreatic cancer are diagnosed with diabetes. We don't know why or how this happens, but understanding this link between diabetes and pancreatic cancer could hold a vital key to earlier diagnosis.
Pancreatic Cancer UK Discovery and Translational Research Forum, 13 & 14 June 2022
Research Involvement Network opportunity: Join a Patient Advisory Panel and help update the Quality of Life questionnaire for pancreatic cancer
Introducing SABR treatment for pancreatic cancer
In Autumn 2020, Pancreatic Cancer UK helped to submit a proposal to NHS England, asking them to commission a type of radiotherapy called SABR (Stereotactic Ablative Body Radiotherapy), for people with locally advanced pancreatic cancer (LAPC). Now, SABR treatment has been commissioned for rollout in England, thanks to a group of healthcare professionals and Pancreatic Cancer UK's Research Involvement Network (RIN).
NEW Career Progression Fellowships
Find out more about the Pancreatic Cancer UK Research Innovation Fund and how you can apply.